Evidence map›Paper›PMID 24482730›Full record

ArticleACS medicinal chemistry letters2013

Rational Design of Novel Pyridinol-Fused Ring Acetaminophen Analogues.

Roman V Shchepin, Wei Liu, Huiyong Yin, Irene Zagol-Ikapitte, Taneem Amin, Byeong-Seon Jeong, L Jackson Roberts, John A Oates, Ned A Porter, Olivier Boutaud

Open access · greenAbstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. The isoprostanes--25 years later.Biochimica et biophysica acta · 2015
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Roman V ShchepinDepartment of Chemistry, Vanderbilt University, 7330 Stevenson Center, Station B 351822, Nashville, Tennessee 37235, United States.
Wei LiuDepartment of Chemistry, Vanderbilt University, 7330 Stevenson Center, Station B 351822, Nashville, Tennessee 37235, United States.
Huiyong YinDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 536 Robinson Research Building, Nashville, Tennessee 37232-6602, United States.
Irene Zagol-IkapitteDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 536 Robinson Research Building, Nashville, Tennessee 37232-6602, United States.
Taneem AminDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 536 Robinson Research Building, Nashville, Tennessee 37232-6602, United States.
Byeong-Seon JeongDepartment of Chemistry, Vanderbilt University, 7330 Stevenson Center, Station B 351822, Nashville, Tennessee 37235, United States.
L Jackson RobertsDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 536 Robinson Research Building, Nashville, Tennessee 37232-6602, United States ; Department of Pharmacology, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 536 Robinson Research Building, Nashville, Tennessee 37232-6602, United States.
John A OatesDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 536 Robinson Research Building, Nashville, Tennessee 37232-6602, United States.
Ned A PorterDepartment of Chemistry, Vanderbilt University, 7330 Stevenson Center, Station B 351822, Nashville, Tennessee 37235, United States.
Olivier BoutaudDepartment of Pharmacology, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 536 Robinson Research Building, Nashville, Tennessee 37232-6602, United States.
Vanderbilt University Medical Center · USVanderbilt University · US

Funding

THE PHARMACOLOGY OF INHIBITORS OF HEME PROTEIN-CATALYZED LIPID PEROXIDATIONP50GM015431 · NIGMS · VANDERBILT UNIVERSITY · PI CAPRIOLI, RICHARD M · 1985 to 2010
$15.0M
Therapeutic Modulation of Endothelial Cell TetrahydrobiopterinP01GM015431 · NIGMS · VANDERBILT UNIVERSITY · PI MARNETT, LAWRENCE J. · 2011 to 2015
$9.5M
NIGMS NIH HHS P01 GM015431NIGMS NIH HHS P50 GM015431
6 · The paper itself

Abstract

Acetaminophen (ApAP) is an electron donor capable of reducing radicals generated by redox cycling of hemeproteins. It acts on the prostaglandin H synthases (cyclooxygenases; COXs) to reduce the protoporphyrin radical cation in the peroxidase site of the enzyme, thus preventing the intra-molecular electron transfer that generates the Tyr385 radical required for abstraction of a hydrogen from arachidonic acid to initiate prostaglandin synthesis. Unrelated to this pharmacological action, metabolism of ApAP by CYPs yields an iminoquinone electrophile that is responsible for the hepatotoxicity, which results from high doses of the drug. We synthesized novel heterocyclic phenols predicted to be electron donors. Two of these inhibited the oxygenation of arachidonic acid by PGHS-1 and myoglobin and also were shown to be more metabolically stable and exhibited less direct cytotoxicity than acetaminophen. They are leading candidates for studies to determine whether they are free of the metabolism-based hepatotoxicity produced by acetaminophen.

Indexed as

Acetaminophenheterocyclic phenolsstabilitysynthesistoxicity

Identifiers

PMID24482730
PMCPMC3904457
OpenAlexW1977156604

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.